A Study to Investigate the Potential Impact of Organic Anion Transporter 3 Inhibition by Probenecid on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
Price : $35 *
At a glance
- Drugs Baricitinib (Primary) ; Probenecid
- Indications Diabetic nephropathies; Gout; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2013 New trial record
- 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.